2,2'-Disubstituted Biphenyls: Synthesis and Suppressive Effect against Carbon Tetrachloride-Induced Liver Injury

Kazuhiko Kondo,^a Masami Takahashi,^a Hiroshi Ohmizu,^a Mamoru Matsumoto,^b Ikuhiko Taguchi,^a and Tameo Iwasaki*,^a

Research Laboratory of Applied Biochemistry, Tanabe Seiyaku Co., Ltd., 3–16–89 Kashima, Yodogawa, Osaka 532, Japan and Pharmacological Research Laboratory, Tanabe Seiyaku Co., Ltd., 2–2–50 Kawagishi, Toda, Saitama 335, Japan. Received May 12, 1993

2,2'-Disubstituted biphenyl compounds (1—15) were synthesized by using the Ullmann coupling reaction as a key step. The suppressive effect of these compounds against CCl₄-induced liver injuries in mice was evaluated. An unsymmetrical biphenyl (14f) exhibited the most potent activity. The structure-activity relationship is discussed.

Keywords 2,2'-disubstituted biphenyl; Ullmann coupling reaction; liver-protective activity; carbon tetrachloride-induced liver injury

Lignans of the dibenzo [a,c] cyclooctene series, e.g., gomisins A, B and C, deoxyschizandrin, and wuweizisu C have recently attracted considerable interest because of their protective activities against liver injury. 1-5) These compounds have a 2,2'-disubstituted biphenyl skeleton which appears to be an essential structure for exhibiting the liver-protective activity. Furthermore, diphenic acid derivatives, represented by dimethyl 4,4'-dimethoxy-5,6,5',6',-bis(methylenedioxy)biphenyl-2,2'-dicarboxylate (DDB, 1a), are also well-known to show potent liverprotective activity.^{2,5)} Thus, 2,2'-disubstituted biphenyl compounds are particularly attractive candidates for new liver-protective agents. However, due to the difficulties encountered in the synthesis of these compounds, their liver-protective activities have not yet been studied systematically. In the course of our synthetic studies of lignans, we have developed a new method for the synthesis of 2,2'-disubstituted unsymmetrical biphenyls based on the intramolecular Ullmann coupling reaction directed by salicyl alcohol as a template.⁶⁾ These synthetic studies

prompted us to examine the liver-protective activity of the 2,2'-disubstituted biphenyls systematically. We now report the synthesis of a number of 2,2'-disubstituted biphenyls (1—15) (Chart 1) and their suppressive effect against CCl_4 -induced liver injury.

Chemistry The symmetrical biphenyl compounds (1a—e) were synthesized by the Ullmann coupling reaction of the corresponding methyl 2-halobenzoate derivatives (16a—e) according to the reported method^{7,8)} (Chart 2).

The unsymmetrical biphenyl compounds (1f—i, 2f, 4—15) were synthesized from the corresponding cyclic biphenyls (17, 18) which were prepared by the template-directed intramolecular Ullmann coupling reaction developed by us⁶⁾ (Chart 2). Thus, the ester exchange reaction of 17f—h^{6c)} and 17j took place cleanly under acidic conditions to afford the corresponding diesters (1f—h, j, 2f) in 85—90% yields. Hydrogenolysis of 1j by using palladium on charcoal afforded the phenol derivative (1i) in 90% yield. The diamide derivatives (4f—6f) were synthesized by the condensation of amines and 19f,^{6c)}

 1a-i: R7=R8=OMe
 10f: R7=NHCH2CH2OH, R8=O-(2-Me-Ph)

 2f: R7=R8=OEt
 11f: R7=NH(CH2)5CH3, R8=O-(2-Me-Ph)

 3f: R7,R8=-O(CH2)3O 12f: R7=NHCH2CH2OH, R8=O-(2-Me-Ph)

 4f: R7=R8=NHEt
 12f: R7=N NCH2CH2OH, R8=O-(2-Me-Ph)

 5f: R7=R8=NHC(Me)2CH2OH
 13f: R7=N NMe, R8=O-(2-Me-Ph)

 7f: R7=NEt2, R8=OEt
 14f: R7=O-(2-Me-Ph), R8=NHC(Me)2CH2OH

 8f: R7=NEt2, R8=O-(2-Me-Ph)
 15f: R7=O-(2-Me-Ph), R8=N NCH2CH2OH

a: $R^1 = R^6 = OMe$, $R^2, R^3 = R^4, R^5 = -OCH_2O$ -; b: $R^1 = R^6 = OMe$, $R^2 = R^3 = R^4 = R^5 = OAc$; c: $R^1 = R^2 = R^3 = R^4 = R^5 = R^6 = OMe$; d: $R^1, R^2 = R^5, R^6 = -OCH_2O$ -, $R^3 = R^4 = H$; e: $R^1 = R^6 = H$, $R^2, R^3 = R^4, R^5 = -OCH_2O$ -; f: $R^1 = H$, $R^2, R^3 = -OCH_2O$ -, $R^4 = R^5 = R^6 = OMe$; g: $R^1 = H$, $R^2, R^3 = -OCH_2O$ -, $R^4 = R^5 = R^6 = OMe$; h: $R^1 = R^4 = H$, $R^2, R^3 = -OCH_2O$ -, $R^5 = OCH_2O$ -,

Chart

© 1994 Pharmaceutical Society of Japan

January 1994 63

Chart 3

which was prepared by the saponification of the cyclic biphenyl (18f). ^{6c)} Furthermore, the monoamide derivatives (7f—15f) were also synthesized from the cyclic biphenyls (17f, 18f). ^{6c)} Thus, hydrogenolysis of 17f and 18f in dioxane using palladium on charcoal proceeded regioselectively to afford the corresponding monoesters (20f, 21f) ^{6c)} in 82—95% yields. Condensations of 20f and 21f with a variety of amines were carried out by the usual method to afford the corresponding monoamides (8f—15f) in 76—91% yields. The ethyl ester (7f) was obtained in a good yield by treatment of 8f with NaOEt in EtOH. Furthermore, the cyclic biphenyl compound (3f) was prepared by the intramolecular Ullmann coupling reaction of 23, which was synthesized by the acylation of 22 (Chart 3).

Biological Results and Discussion The suppressive effect of the 2,2'-disubstituted biphenyls prepared above was evaluated against CCl₄-induced liver injury in mice after oral administration at a dose of 100 mg/kg. The results are summarized in Table I. The activity was evaluated in terms of the suppressive effect of these compounds on the CCl₄-induced elevation of the glutamate pyruvic transaminase (GPT) activity in mice.

We first evaluated the suppressive effect of the biphenyls (1b—i) having two methoxycarbonyl groups at the 2 and 2' positions in order to examine the effect of the oxygen functionalities attached to the aromatic rings on the activity. Among the symmetrical biphenyls (1b-e), only 1e having methylenedioxy groups at the 5,6 and 5',6' positions was active. We next examined the activity of the unsymmetrical biphenyls (1f-i) having a 5,6-methylenedioxy group on one benzene ring and oxygen functionalities other than the methylenedioxy group on the other benzene ring. We found that all compounds exhibited the activity except for 1i (having a phenolic hydroxyl group). These results clearly indicate that the biphenyl skeleton having a 5,6-methylenedioxy group on at least one of the two benzene rings is important for exhibiting the activity. Among the unsymmetrical biphenyls, 1g showed the most potent activity, which was comparable to that of DDB. This result is in marked contrast to that in the case of the cyclic biphenyl lignans, such as gomisin A, in which a methylenedioxy group at the 4,5 or 4',5' position is essential for exhibiting the activity.3)

In order to find compounds having much more potent activity, we further examined the effect of the substituents

Table I. Effect of 2,2'-Disubstituted Biphenyls on CCl₄-Induced Liver Injury in Mice^{a)}

Compd. No.	Suppressive activity ^b	
1a (DDB)	+++	
1b `	_	
1c	_	
1d		
1e	++	
1f	+++	
1g	++	
1h	++	
1i	_	
2f	++++	
3f	_	
4f	+++	
5f	++++	
6f	+++	
7f	++	
8f	+++	
9f	++	
10f	+	
11f	++	
12f	++++	
13f	+	
14f	++++	
15f	++	

a) A test compound was orally administered at a dose of $100 \,\text{mg/kg}$. b) Suppression (%) of the CCl₄-induced elevation of GPT in mice: $- \le 20$, $20 \le + \le 40$, $40 < + + \le 60$, $60 < + + + \le 80$, 80 < + + + + +.

at the 2 and 2' positions on the activity. Thus, we examined the activity of the diesters (2f, 3f) having ester groups other than methoxycarbonyl groups at the 2 and 2' positions. Of these compounds, 2f showed potent activity, while 3f lacked the activity. It is noteworthy that the activity of 2f is more potent than that of DDB.

We also examined the activity of the diamide derivatives (4f—6f). All of them showed activity comparable to or stronger than that of DDB. The 2,2'-bis(N,N-diethylcarboxamide) derivative (5f) showed the most potent activity. These results prompted us to examine the activity of the monoamide (7f). However, 7f unexpectedly showed only weak activity. On the other hand, 8f, an o-tolyl analog of 7f, showed almost the same activity as that of DDB. We further evaluated 9f—15f having an o-tolyloxycarbonyl group and a carbamoyl group. All of these compounds were found to have the activity, and 12f and 14f showed very potent activity.

On the basis of these results, we selected 2f, 5f, 12f and 14f for further evaluation. The results are summarized in Table II. The activity of these compounds was evaluated at doses of 100, 30 and 10 mg/kg. Compound 14f showed the most potent activity, being more potent than DDB. The acute toxicity of these compounds was also examined. No acute toxicity was detected with compound 14f. Thus, 14f is considered to be a potential candidate for a liver-protective agent. Further studies of 14f are in progress, and the results will be reported elsewhere.

Experimental

Melting points were determined in open capillary tubes on a Yamato MP-21 melting point apparatus, without correction. Infrared (IR) spectra were obtained using a Perkin Elmer 1640 IR spectrometer. NMR spectra

TABLE II. Suppressive Effect and Acute Toxicity of 1a, 2f, 5f, 12f and

Compd. No.	Dose (mg/kg)	Suppression (%) of the CCl ₄ -induced elevation of GPT	Acute toxicity ^a
2f	10	-2.3	0/3
	30	26.2	
	100	84.7 ^{b)}	
5f	10	5.4	1/3
	30	31.6	
	100	$90.9^{b)}$	
12f	10	-5.4	3/3
	30	14.9	
	100	97.8^{b}	
14f	10	12.2	0/3
	30	$61.5^{c)}$	
	100	95.5 ^{b)}	*
1a (DDB)	10	13.3	0/3
	30	35.3	
	100	$74.5^{b)}$	

a) Mortality (number of mice that died/number of mice tested) when a compound was orally administered at a dose of $1000 \,\mathrm{mg/kg}$. b) Significantly different from control, p < 0.01. c) p < 0.05.

were recorded on a Hitachi R-90 or a Bruker AC-200 instrument using Me₄Si as the internal standard. Mass spectra (MS) were obtained on a Hitachi M-60 or Hitachi M-2000A spectrometer. Thin layer chromatography was carried out on silica gel (Merck type 60H). Dimethyl formamide (DMF), purchased from Katayama Kagaku, was dried over molecular sieves (4 A) and used without further purification. All other solvents were purchased from Katayama Kagaku and used without purification. Copper powder was purchased from Katayama Kagaku and used immediately after purification. 9)

Preparation of the Diesters (1a—e) The diesters (1a—e) were prepared according to the reported method. ^{7,8)} Compound 1a: mp 158—159 °C (lit. ⁵⁾ 154—156 °C). Compound 1b was prepared from methyl 3,4-bis(acetoxy)-2-bromo-5-methoxybenzoate. Compound 1b: colorless needles, mp 165—166 °C. IR (KBr): 1788, 1776, 1720, 1336, 1096 cm $^{-1}$. ¹H-NMR (CDCl₃) δ: 1.92 (6H, s), 2.25 (6H, s), 3.58 (6H, s), 3.90 (6H, s), 7.52 (2H, s). MS m/z: 562 (M $^{+}$). Anal. Calcd for C₂₆H₂₆O₁₄: C, 55.52; H, 4.66. Found: C, 55.46; H, 4.71. Compound 1c: mp 151—152 °C). Compound 1e was prepared from methyl 2-iodo-3,4-methylenedioxy-benzoate. Compound 1c: colorless needles, mp 186 °C. IR (Nujol): 1702 cm $^{-1}$. ¹H-NMR (CDCl₃) δ: 3.64 (6H, s), 5.94 (4H, s), 6.84 (2H, d, J=2 Hz), 7.71 (2H, d, J=2 Hz). MS m/z: 358 (M $^{+}$). Anal. Calcd for C₁₈H₁₄O₈: C, 60.34; H, 3.74. Found: C, 60.33; H, 3.75.

benzodioxacycloundecin-6,14-dione (17j) 2-Iodo-3,4-methylenedioxybenzoyl chloride (3.1 g, 10 mmol) was added in portions to a solution of salicyl alcohol (1.24 g, 10 mmol), Et₃N (3.34 ml, 24 mmol) and 4-dimethylaminopyridine (12 mg, 0.1 mmol) in dimethylacetamide (50 ml) over a period of 30 min at -30—-20 °C. The reaction mixture was warmed to room temperature and stirred for 6 h at the same temperature, then again cooled to -30—-20 °C. To this mixture was added dropwise a solution of 2-iodo-4-benzyloxy-5-methoxybenzoyl chloride (4.03 g, 10 mmol) in methylene chloride (20 ml) over a period of 30 min at -30-20 °C. The reaction mixture was warmed to room temperature and stirred for 14h at the same temperature, then poured into water (300 ml) and extracted with ethyl acetate (3×200 ml). The combined organic layer was washed with aqueous NaHCO3 solution and brine, and dried over MgSO4. The organic layer was evaporated under reduced pressure and the residue was purified by column chromatography on silica gel (ethyl acetate: hexane = 2:1) to afford 2-(2-iodo-3,4-methylene-dioxybenzoyloxymethyl)phenyl 4-benzyloxy-2-iodo-5-metoxybenzoate (6.1 g, 8.0 mmol): colorless needles, mp 134-136 °C. IR (Nujol): 1740, $1725 \,\mathrm{cm}^{-1}$. ¹H-NMR (CDCl₃) δ : 3.86 (3H, s), 5.16 (2H, s), 5.36 (2H, s), 6.04 (2H, s), 6.66 (1H, d, J=8 Hz), 7.15—7.65 (11H, m), 7.69 (1H, s). MS m/z: 764 (M⁺). Anal. Calcd for $C_{30}H_{22}I_2O_8$: C, 47.14; H, 2.90; I, 33.21. Found: C, 47.37; H, 2.85; I, 33.09. A solution of the diester

(1.53 g, 2.0 mmol) in DMF (10 ml) was added dropwise over a period of 3 h to refluxing DMF (10 ml) containing activated copper powder⁹⁾ (1.27 g, 20 mmol). After the addition was over, the reaction mixture was refluxed for an additional 1 h. It was then cooled and the insoluble materials were filtered off. The filtrate was evaporated to dryness under reduced pressure. The residue was dissolved in ethyl acetate (50 ml) and the solution was washed with water, dried over MgSO₄, and evaporated to dryness under reduced pressure. The residue was purified by column chromatography on silica gel (ethyl acetate: hexane = 2:1) to afford 17i (888 mg, 1.74 mmol): a colorless amorphous powder. IR (Nujol): 1750, 1725 cm⁻¹. ¹H-NMR (CDCl₃) δ : 3.97 (3H, s), 4.72 (1H, d, J=11 Hz), 5.0—5.9 (2H, m), 5.75—6.2 (3H, m), 6.69 (1H, d, J=8.5 Hz), 7.05—7.5 (12H, m). MS m/z: 510 (M⁺). Anal. Calcd for $C_{30}H_{22}O_8$: C, 70.58; H, 4.34. Found: C, 70.69; H, 4.51.

Preparation of the Diesters (1f—h, j, 2f) A solution of the cyclic biphenyl (17f) (870 mg, 2.0 mmol) and sulfonic acid (0.1 ml) in methanol (200 ml) was refluxed for 14 h. The mixture was evaporated to dryness *in vacuo* and the residue was poured into a mixture of water (50 ml) and ethyl acetate (50 ml). The organic layer was separated and the aqueous layer was further extracted with ethyl acetate (100 ml). The combined organic layer was washed with water, and dried over MgSO₄. The solvent was evaporated off *in vacuo*. The residue was crystallized from diisopropyl ether to afford **1f** (670 mg, 1.8 mmol): colorless needles, mp 121 °C. IR (KBr): 1720, 1600 cm $^{-1}$. 1 H-NMR (CDCl₃) δ : 3.59 (3H, s), 3.65 (3H, s), 3.86 (3H, s), 3.94 (3H, s), 5.94 (2H, s), 6.67 (1H, s), 6.82 (1H, d, J=8 Hz), 7.60 (1H, s), 7.65 (1H, d, J=8 Hz). MS m/z: 374 (M $^+$). *Anal.* Calcd for C₁₉H₁₈O₈: C, 60.96; H, 4.85. Found: C, 60.92; H, 4.86.

Compounds 1g, h, j and 2f were prepared by the same procedure as described above. Compound 1g: colorless needles, mp 115 °C. IR (KBr): 1722 cm $^{-1}.$ $^{1}\text{H-NMR}$ (CDCl3) $\delta\colon 3.61$ (9H, s), 3.92 (6H, s), 5.93 (2H, s), 6.82 (1H, d, J=8 Hz), 7.38 (1H, s), 7.68 (1H, d, J=8 Hz). MS m/z: 404 (M⁺). Anal. Calcd for C₂₀H₂₀O₉: C, 59.41; H, 4.99. Found: C, 59.38; H, 4.89. Compound 1h: colorless needles, mp 139-141 °C. IR (KBr): 1720, 1718 cm⁻¹. ¹H-NMR (CDCl₃) δ : 3.64 (6H, s), 5.94 (2H, s), 6.04 (2H, s), 6.64 (1H, s), 6.79 (1H, d, J=8 Hz), 7.51 (1H, s), 7.64 (1H, d, J=8 Hz). MS m/z: 358 (M⁺). Anal. Calcd for $C_{18}H_{14}O_8$: C, 60.34; H, 3.94. Found: C, 60.41; H, 3.89. Compound 1j: colorless needles, mp 118—119 °C. IR (KBr): 1705, 1695 cm $^{-1}$. 1 H-NMR (CDCl $_{3}$) δ : 3.53 (3H, s), 3.65 (3H, s), 3.95 (3H, s), 5.13 (2H, s), 5.95—6.15 (2H, m), 6.70 (1H, s), 6.79 (1H, d, J=8 Hz), 7.2—7.5 (5H, m), 7.60 (1H, s), 7.61 (1H, s)d, J = 8 Hz). MS m/z: 450 (M⁺). Anal. Calcd for $C_{25}H_{22}O_8$: C, 66.66; H, 4.92. Found: C, 66.77; H, 5.01. Compound 2f: colorless needles, mp 82—83 °C. IR (Nujol): 1722 cm⁻¹. ¹H-NMR (CDCl₃) δ : 1.01 (3H, t, J=7 Hz), 1.03 (3H, t, J=7 Hz), 3.88 (3H, s), 3.96 (3H, s), 4.01 (2H, q, J=7 Hz), 4.10 (2H, q, J=7 Hz), 5.95 (2H, s), 6.68 (1H, s), 6.84 (1H, d, J=8 Hz), 7.61 (1H, s), 7.65 (1H, d, J=8 Hz). MS m/z: 402 (M⁺). Anal. Calcd for C₂₁H₂₂O₈: C, 62.68; H, 5.51. Found: C, 62.39; H, 5.66.

Dimethyl 5-Hydroxy-4-methoxy-5',6'-methylenedioxybiphenyl-2,2'-dicarboxylate (1i) Hydrogenolysis of 1j (900 mg, 2.0 mmol) using 10% palladium on charcoal (100 mg) was carried out in dioxane (50 ml) for 5 h under a hydrogen atmosphere (2.0 kg/cm²). The insoluble materials were filtered off and the filtrate was evaporated to dryness *in vacuo*. The residue was crystallized from diisopropyl ether to give 1i (650 mg, 1.8 mmol): colorless needles, mp 172—173 °C. IR (KBr): 3400, 1710 cm $^{-1}$. ¹H-NMR (CDCl₃) δ: 3.61 (1H, s), 3.64 (6H, s), 3.96 (3H, s), 5.93 (2H, s), 6.75 (1H, s), 6.80 (1H, d, J=7 Hz), 7.59 (1H, s), 7.63 (1H, d, J=7 Hz). MS m/z: 360 (M $^+$). *Anal.* Calcd for C₁₈H₁₆O₈: C, 60.00; H, 4.48, Found: C, 60.02; H, 4.46.

Preparation of Diamides (4—6) SOCl₂ (2.4 g, 20 mmol) and DMF (1 drop) were added to a solution of 19f^{6c)} (690 mg, 2.0 mmol) in dioxane (10 ml), and the mixture was refluxed for 0.5 h, then evaporated to dryness in vacuo. The residue was taken up in toluene (20 ml) and the solution was evaporated to dryness in vacuo. The residue were dissolved in methylene chloride (20 ml) containing 4-dimethylaminopyridine (490 mg, 4.0 mmol), then ethylamine (230 mg, 5.0 mmol) was added dropwise at 0-5°C. The mixture was stirred for 14h at room temperature, and washed with 5% aqueous citric acid solution and water. The organic layer was dried over MgSO₄ and the mixture was evaporated to dryness in vacuo. The residue was crystallized from diisopropyl ether to afford 4f (680 mg, 1.7 mmol): colorless needles, mp 196—197 °C. IR (Nujol): 3280, $1620 \,\mathrm{cm}^{-1}$. ¹H-NMR (CDCl₃) δ : 0.90 (3H, t, $J = 6 \,\mathrm{Hz}$), 0.93 (3H, t, J = 6 Hz), 3.0—3.45 (4H, m), 3.81 (3H, s), 3.91 (3H, s), 5.89 (2H, s), 6.60 (1H, s), 6.7—7.2 (5H, m). MS m/z: 400 (M⁺). Anal. Calcd for C₂₁H₂₄N₂O₆: C, 62.99; H, 6.04; N, 7.00. Found: C, 62.78; H, 6.23; N, 6.81.

The diamides (**5f**, **6f**) were prepared from **19f** by the same procedure as described above. Compound **5f**: colorless needles, mp 148—149 °C. IR (Nujol): 1630, 1615 cm $^{-1}$. ¹H-NMR (CDCl $_3$) δ : 0.85 (3H, t, J=7 Hz), 0.89 (3H, t, J=7 Hz), 1.17 (6H, t, J=7 Hz), 2.8—3.9 (8H, m), 3.89 (6H, s), 5.8—5.95 (2H, m), 6.7—7.0 (3H, m), 7.13 (1H, s). MS m/z: 456 (M $^+$). Anal. Calcd for $C_{25}H_{32}N_2O_6$: C, 65.77; H, 7.07; N, 6.15. Found: C, 65.64; H, 6.92; N, 5.93. Compound **6f**: colorless needles, mp 182—184 °C. IR (Nujol): 3280, 1640 cm $^{-1}$. ¹H-NMR (CDCl $_3$) δ : 1.05 (6H, s), 1.12 (6H, s), 3.4 (4H, br s), 3.83 (3H, s), 3.93 (3H, s), 4.40 (1H, br s), 4.65 (1H, br s), 5.93 (2H, s), 6.7—7.2 (6H, m).Anal. Calcd for $C_{25}H_{32}N_2O_8$: C, 61.46; H, 6.60; N, 5.73. Found: C, 61.52; H, 6.71; N, 5.49.

Preparation of the Monoamides (8—15) The monoamides (8f—15f) were prepared from the corresponding carboxylic acids (20f, 21f) by the same procedure as described above. Compound 8f: colorless needles, mp 145—146 °C. IR (Nujol): 1705, 1640 cm⁻¹. ¹H-NMR (CDCl₃) δ : 0.79 (3H, t, J = 6.8 Hz), 0.83 (3H, t, J = 6.8 Hz), 2.22 (3H, s), 2.7—3.15 (2H, m), 3.2—3.75 (2H, m), 3.95 (3H, s), 4.00 (3H, s), 5.90 (2H, s), 6.80 (1H, d, J = 7.9 Hz), 6.85 (1H, d, J = 7.9 Hz), 6.95—7.3 (5H, m), 7.76 (1H, s). MS m/z: 491 (M⁺). Anal. Calcd for C₂₈H₂₉NO₇: C, 68.41; H, 5.95; N, 2.85. Found: C, 68.16; H, 5.91; N, 3.15. Compound 9f: colorless needles, mp 177—181 °C. IR (Nujol): 1705, 1640 cm⁻¹. ¹H-NMR (CDCl₃) δ : 0.84 (3H, s), 0.99 (3H, s), 2.17 (3H, s), 3.2—3.6 (3H, m), 3.90 (3H, s), 4.01 (3H, s), 4.9—6.3 (3H, m), 6.7—7.35 (7H, m), 7.69 (1H, s). Anal. Calcd for C₂₈H₂₉NO₈: C, 66.26; H, 5.76; N, 2.76. Found: C, 66.27; H, 5.8; N, 2.63. Compound 10f: colorless needles, mp 148-150°C. IR (Nujol): 3370, 1695, 1660 cm⁻¹. ¹H-NMR (CDCl₃) δ : 2.16 (3H, s), 2.1—2.3 (1H, m), 3.1—3.5 (4H, m), 3.90 (3H, s), 3.99 (3H, s), 5.90—5.95 (2H, m), 6.6 (1H, br s), 6.77 (1H, d, J=8.5 Hz), 6.80 (1H, s), 6.9—7.3 (5H, m), 7.69 (1H, s). Anal. Calcd for C₂₆H₂₅NO₈: C, 65.13; H, 5.26; N, 2.92. Found: C, 65.33; H, 5.30; N, 2.84. Compound 11f: colorless needles, mp 117—118 °C. IR (Nujol): 3400, 1735, 1660 cm⁻¹. ¹H-NMR $(CDCl_3)$ δ : 0.7—1.4 (11H, m), 2.16 (3H, s), 2.8—3.4 (2H, m), 3.89 (3H, s), 3.98 (3H, s), 5.91 (2H, s), 6.0 (1H, br s), 6.7—7.3 (7H, m), 7.67 (1H, s). MS m/z: 519 (M⁺). Anal. Calcd for $C_{30}H_{33}NO_7$: C, 69.34; H, 6.40; N, 2.69. Found: C, 69.50; H, 6.41; N, 2.65. Compound 12f: colorless needles, mp 92—95 °C. IR (Nujol): 3400, 1730, 1600 cm $^{-1}$. 1 H-NMR (CDCl₃) δ : 2.1—2.6 (5H, m), 2.22 (3H, s), 2.8—3.7 (8H, m), 3.91 (3H, s), 4.00 (3H, s), 5.90 (2H, s), 6.7—7.3 (7H, m), 7.73 (1H, s). Anal. Calcd for C₃₀H₃₂N₂O₈: C, 65.68; H, 5.88; N, 5.11. Found: C, 65.42; H, 5.97; N, 4.86. Compound 13f: colorless needles, mp 156—158 °C. IR (Nujol): 1745, 1620 cm $^{-1}.$ $^{1}\text{H-NMR}$ (CDCl3) $\delta:$ 1.5—2.4 (4H, m), 2.12 (3H, s), 2.21 (3H, s), 3.0-3.7 (4H, m), 3.90 (3H, s), 3.97 (3H, s), 5.88 (2H, s), 6.0—7.35 (6H, m), 7.66 (1H, s), 7.99 (1H, s). MS m/z: 518 (M⁺). Anal. Calcd for C₂₉H₃₀N₂O₇: C, 67.17; H, 5.83; N, 5.40. Found: C, 67.45; H, 5.88; N, 5.29. Compound 14f: colorless needles, mp 155-156 °C. IR (Nujol): 3320, 1700, 1660 cm $^{-1}$. ¹H-NMR (CDCl₃) δ : 0.91 (3H, s), 1.00 (3H, s), 2.12 (3H, s), 3.2—3.65 (3H, m), 3.84 (3H, s), 3.90 (3H, s), 4.85—5.1 (1H, m), 6.00 (2H, s), 6.47 (1H, br s), 6.7—7.35 (6H, m), 7.73 (1H, d, J=8 Hz). MS m/z: 507 (M⁺). Anal. Calcd for $C_{28}H_{29}NO_8$: C, 66.26; H, 5.76; N, 2.76. Found: C, 66.54; H, 5.58; N, 2.54. Compound 15f: colorless needles, mp 102—103°C. IR (Nujol): 3400, 1720, $1620\,\mathrm{cm^{-1}}$. 1 H-NMR (CDCl₃) δ : 2.0—2.6 (5H, m), 2.17 (3H, s), 3.05-3.7 (8H, m), 3.85 (3H, s), 3.88 (3H, s), 6.00 (1H, d, J = 0.9 Hz), 6.04 (1H, d, J=0.9 Hz), 6.7—7.3 (7H, m), 7.86 (1H, d, J=8.3 Hz). MS $\it m/z$: 548 (M $^+$). Anal. Calcd for $\rm C_{30}H_{32}N_2O_8$: C, 65.68; H, 5.88; N, 5.11. Found: C, 65.66; H, 5.84; N, 5.22

Ethyl 2-(N,N-Diethylcarbamoyl)-4,5-dimethoxy-5',6'-methylenedioxy-biphenyl-2-carboxylate (7f) Compound 8f (750 mg, 2.0 mmol) was added to a solution of sodium ethoxide (50 mg) in ethanol (20 ml), and the mixture was stirred at room temperature for 4h, then poured into 5% aqueous citric acid solution. The whole was extracted with ethyl acetate (2 × 100 ml). The combined organic layer was washed with water, dried over MgSO₄, and evaporated *in vacuo*. The residue was crystallized from ether to afford 7f (710 mg, 1.7 mmol): colorless needles, mp 86—87 °C. IR (Nujol): 1715, 1640 cm $^{-1}$. 1 H-NMR (CDCl₃) δ : 0.82 (6H, t, J=7.1 Hz), 1.14 (3H, t, J=7.1 Hz), 2.65—3.1 (2H, m), 3.25—3.65 (2H, m), 3.91 (3H, s), 3.95 (3H, s), 4.19 (2H, br q, J=7.1 Hz), 5.86 (1H, d, J=1.1 Hz), 5.94 (1H, d, J=1.1 Hz), 6.85 (1H, d, J=8.0 Hz), 7.26 (1H, s), 7.50 (1H, s). MS m/z: 429 (M $^{+}$). Anal. Calcd for $C_{23}H_{27}NO_7$: C, 64.32; H, 6.34; N, 3.26. Found: C, 64.13; H, 6.35; N, 3.17.

1-(2-Iodo-4,5-dimethoxybenzoyloxy)-3-(2-iodo-3,4-methylenedioxy-

benzoyloxy)propane (23) 2-Iodo-3,4-methylenedioxybenzoyl chloride (3.1 g, 10 mmol) was added to a solution of 22 (7.6 g, 100 mmol), Et₃N (3.34 ml, 24 mmol) and 4-dimethylaminopyridine (12 mg, 0.1 mmol) in methylene chloride (50 ml) at 5 °C and the mixture was stirred at room temperature for 14h, then washed with water, saturated aqueous NaHCO3 solution and brine. The organic layer was dried over MgSO4 and evaporated to dryness in vacuo. The residue was dissolved in methylene chloride (50 ml) containing triethylamine (3.34 ml, 24 mmol) and 4-dimethylaminopyridine (12 mg, 0.1 mmol). To this solution was added 2-iodo-4,5-dimethoxybenzoyl chloride (3.3 g, 10 mmol) at 5 °C, and the mixture was stirred at room temperature for 14 h, then washed with water, saturated aqueous NaHCO3 solution and brine, and dried over MgSO₄. The solvent was evaporated to dryness in vacuo and the residue was purified by column chromatography on silica gel (ethyl acetate: hexane = 2:1) to give 23 (4.7 g, 7.4 mmol): colorless needles, mp 132—133 °C. IR (Nujol): 1720 cm⁻¹. ¹H-NMR (CDCl₃) δ : 2.28 (2H, q, J=6 Hz), 3.82 (3H, s), 3.88 (3H, s), 4.52 (4H, t, J=6 Hz), 6.10 (2H, s), 6.74 (1H, d, J = 8.5 Hz), 7.38 (1H, s), 7.43 (1H, s), 7.55 (1H, d, J = 8.5 Hz). MS m/z: 640 (M⁺). Anal. Calcd for $C_{20}H_{18}I_2O_8$: C, 37.52; H, 2.83. Found: C, 37.59; H, 2.77.

8,9-Dihydro-13,14-dimethoxy-1,2-methylenedioxy-7H-dibenzo[g,i]-[1,5]dioxacycloundecine-5,11-dione (3f) A solution of the diester 23 (1.17 g, 2.0 mmol) in DMF (10 ml) was added dropwise over a period of 3h to refluxing DMF (10 ml) containing activated copper powder (1.27 g, 20 mmol). After the addition was over, the reaction mixture was refluxed for an additional 1 h, then cooled, and the insoluble materials were filtered off. The filtrate was evaporated to dryness in vacuo. The residue was dissolved in ethyl acetate (50 ml) and the solution was washed with water dried over MgSO₄. After the solvent had been removed in vacuo, the residue was purified by column chromatography on silica gel (hexane:chloroform:ethylacetate=3:3:1) to afford 3f (650 mg, 1.68 mmol) as colorless needles, mp 197—199 °C. IR (Nujol): 1725 cm⁻¹. ¹H-NMR (CDCl₃) δ : 2.0—2.4 (2H, m), 3.9—4.35 (2H, m), 3.90 (6H, s), 4.6-4.95 (2H, m), 5.9-6.1 (2H, m), 6.76 (1H, d, J=8 Hz), 6.95 (1H, s), 7.16 (1H, d, J = 8 Hz), 7.19 (1H, s). MS m/z: 386 (M⁺). Anal. Calcd for C₂₀H₁₈O₈: C, 62.17; H, 4.70. Found: C, 62.19; H, 4.74.

Evaluation of Biological Activity Groups of 3 ddY male mice, weighing 25—30 g, were used. Test compounds were orally administered to mice at a dose of 100, 30 or 10 mg/kg, 3 h before oral administration of 75 ml/kg of CCl₄. Mice were starved for 24 h after the injection of CCl₄, then killed, and blood samples were collected from the abdominal aorta. The plasma GPT activity was measured according to the method

of Reimann and Frankel. $^{12)}$ The suppressive effect of each compound against CCl_4 -induced liver injury was evaluated in terms of the suppression (%) of elevation of GPT activity. The suppression (%) was calculated from the following equation (Tables I and II).

suppression (%) of elevation of GPT activity

$$= \{1 - (A - B)/(C - B)\} \times 100$$

where A is the mean GPT activity of the test compound group, B is the mean GPT activity of the normal control group, and C is the mean GPT activity of the CCl_{4} -treated control group.

Acknowledgement We thank Dr. Tetsuya Tosa, director of our company and Dr. Kazuo Matsumoto, general manager of the Research Coordination Division for their encouragement and interest.

References and Notes

- S. Maeda, K. Sudo, Y. Miyamoto, S. Takeda, M. Shinbo, M. Aburada, Y. Ikeya, H. Taguchi, M. Harada, Yakugaku Zasshi, 102, 579 (1982).
- 2) K. T. Liu, P. Lesca, Chem.-Biol. Interact., 41, 39 (1982).
- H. Hikino, Y. Kiso, H. Taguchi, Y. Ikeya, *Planta Medica*, 50, 213 (1984).
- Y. Kiso, M. Tohkin, H. Hikino, Y. Ikeya, H. Taguchi, *Planta Medica*, 51, 331 (1985).
- W. L. Wu, S. E. Chen, W. L. Chang, C. F. Chen, A. R. Lee, Eur. J. Med. Chem., 27, 353 (1992).
- a) M. Takahashi, T. Kuroda, T. Ogiku, H. Ohmizu, K. Kondo, T. Iwasaki, Tetrahedron Lett., 32, 6919 (1991); b) M. Takahashi, Y. Moritani, T. Ogiku, H. Ohmizu, K. Kondo, T. Iwasaki, ibid., 33, 5103 (1992); c) M. Takahashi, T. Ogiku, K. Okamura, T. Da-te, H. Ohmizu, K. Kondo, T. Iwasaki, J. Chem. Soc., Perkin Trans. 1, 1993, 1473.
- J. Xie, J. Zhou, C. Zhang, J. Yang, H. Jin, J. Chen, Kexue Tongbao, 27, 23 (1982).
- 8) P. E. Fanta, Synthesis, 1974, 9.
- R. C. Fuson, E. A. Cleveland, "Organic Synthesis," Coll. Vol. III, John Wiley & Sons, Inc., New York, 1962, p. 339.
- 10) E. Brown, J.-P. Robin, R. Dhal, Tetrahedron, 38, 2569 (1982).
- 11) S. Ozeki, Yakugaku Zasshi, 85, 206 (1965).
- 12) S. Reimann, S. Frankel, Am. J. Clin. Pathol., 28, 56 (1977).